Monitoring and Adjusting Treatment Regular check-ins with a healthcare provider are essential to monitor these effects and adjust treatment as needed
Ageing Res Rev 112: 102834
Our guide on peptide safety and risks provides essential context
Your weekly program includes: Once-weekly subcutaneous self-injection Dual GLP-1 and GIP receptor agonist Clinically shown to outperform semaglutide for weight loss Reduces appetite, blood sugar, and visceral fat No lab draw required
doi: 10.1056/NEJMoa1612917 252 MarsoSPDanielsGHBrown-FrandsenKKristensenPMannJFNauckMAet al
Differential diagnoses Iatrogenic Chronic use of drugs, e.g., antihistamines, antidepressants, anticholinergics Head and neck radiation Corneal surgery, e.g., LASIK Systemic autoimmune diseases Chronic viral infections Atopic disease: e.g., allergic conjunctivitis Other Age-related sicca syndrome [8] Definition: xerophthalmia and xerostomia in older patients without evidence of Sjogren syndrome Etiology Decreased tear and saliva production (due to age-related interstitial fibrosis, acinar atrophy with fat replacement, ductal dilation, and nonspecific chronic inflammation) Decreased blinking rate Toxicity from topical drugs Risk factors: older age, female sex, medication use (e.g., anticholinergics) Clinical features: See Sicca syndrome above
